Natalizumab treatment reduces endothelial activity in MS patients. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, et al. J Neuroimmunol. 2010 Oct 8; 227(1-2):190-4. Epub 2010 Aug 23. PMID: 20739072. Abstract CommentRecommendBookmarkWatch